XML 57 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)
Preferred Stock
Common stock
Additional paid-in capital
Accumulated other comprehensive income/(loss)
Deferred compensation
Deficit accumulated during development stage
Total
Balance at Aug. 13, 1996                     
Balance (in shares) at Aug. 13, 1996                
Increase (Decrease) in Stockholders' Equity              
Issue of common stock for cash in an underwritten public offering, net of expenses     1,000       1,000
Translation adjustment       (4,000)     (4,000)
Loss for the year           (290,000) (290,000)
Balance at Mar. 31, 1997     1,000 (4,000)   (290,000) (293,000)
Increase (Decrease) in Stockholders' Equity              
Issue of common stock for cash in an underwritten public offering, net of expenses     4,217,000       4,217,000
Issue of common stock for cash in an underwritten public offering, net of expenses (in shares)   38,111          
Issue of shares for IP rights agreement, research & development agreement and license agreement     262,000       262,000
Stock-based compensation     2,002,000   (2,002,000)    
Amortization of deferred stock-based compensation         302,000   302,000
Translation adjustment       55,000     55,000
Loss for the year           (2,534,000) (2,534,000)
Balance at Mar. 31, 1998     6,482,000 51,000 (1,700,000) (2,824,000) 2,009,000
Balance (in shares) at Mar. 31, 1998   38,111          
Increase (Decrease) in Stockholders' Equity              
Amortization of deferred stock-based compensation         406,000   406,000
Translation adjustment       11,000     11,000
Loss for the year           (3,964,000) (3,964,000)
Balance at Mar. 31, 1999     6,482,000 62,000 (1,294,000) (6,788,000) (1,538,000)
Balance (in shares) at Mar. 31, 1999   38,111          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock for cash in an underwritten public offering, net of expenses     12,717,000       12,717,000
Issue of common stock for cash in an underwritten public offering, net of expenses (in shares)   76,984          
Issue of shares on conversion of bridging loan and Loan Note Instrument     1,638,000       1,638,000
Issue of shares on conversion of bridging loan and Loan Note Instrument (in shares)   12,943          
Issue of shares in lieu of cash bonus     164,000       164,000
Issue of shares in lieu of cash bonus (in shares)   1,294          
Issue of shares for IP rights agreement, research & development agreement and license agreement     409,000       409,000
Issue of common stock upon exercise of stock options     40,000       40,000
Issue of common stock upon exercise of stock options (in shares)   324          
Stock-based compensation     167,000   (167,000)    
Amortization of deferred stock-based compensation         433,000   433,000
Translation adjustment       (194,000)     (194,000)
Loss for the year           (5,686,000) (5,686,000)
Balance at Mar. 31, 2000     21,617,000 (132,000) (1,028,000) (12,474,000) 7,983,000
Balance (in shares) at Mar. 31, 2000   129,656          
Increase (Decrease) in Stockholders' Equity              
Stock-based compensation     294,000   (294,000)    
Amortization of deferred stock-based compensation         275,000   275,000
Translation adjustment       (466,000)     (466,000)
Loss for the year           (10,382,000) (10,382,000)
Balance at Mar. 31, 2001     21,911,000 (598,000) (1,047,000) (22,856,000) (2,590,000)
Balance (in shares) at Mar. 31, 2001   129,656          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock for cash in an underwritten public offering, net of expenses (in shares)   779          
Issue of warrants in connection with registered direct offering     1,215,000       1,215,000
Issue of shares for IP rights agreement, research & development agreement and license agreement     183,000       183,000
Issue of shares for IP rights agreement, research & development agreement and license agreement (in shares)   644          
Issue of common stock upon exercise of stock options     106,000       106,000
Stock-based compensation     363,000   (363,000)    
Amortization of deferred stock-based compensation         672,000   672,000
Translation adjustment       191,000     191,000
Loss for the year           (14,853,000) (14,853,000)
Balance at Mar. 31, 2002     23,778,000 (407,000) (738,000) (37,709,000) (15,076,000)
Balance (in shares) at Mar. 31, 2002   131,079          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock upon exercise of stock options     12,000       12,000
Stock-based compensation     (84,000)   84,000    
Amortization of deferred stock-based compensation         305,000   305,000
Translation adjustment       (1,846,000)     (1,846,000)
Loss for the year           (15,542,000) (15,542,000)
Balance at Mar. 31, 2003     23,706,000 (2,253,000) (349,000) (53,251,000) (32,147,000)
Balance (in shares) at Mar. 31, 2003   131,079          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock for cash in an underwritten public offering, net of expenses     27,635,000       27,635,000
Issue of common stock for cash in an underwritten public offering, net of expenses (in shares)   215,755          
Preferred stock conversion   1,000 58,147,000       58,148,000
Preferred stock conversion (in shares)   538,449          
Issue of common stock upon exercise of stock options     115,000       115,000
Issue of common stock upon exercise of stock options (in shares)   936          
Amortization of deferred stock-based compensation         217,000   217,000
Translation adjustment       (1,343,000)     (1,343,000)
Loss for the year           (14,977,000) (14,977,000)
Balance at Dec. 31, 2003   1,000 109,603,000 (3,596,000) (132,000) (68,228,000) 37,648,000
Balance (in shares) at Dec. 31, 2003   886,219          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock for cash in an underwritten public offering, net of expenses     8,541,000       8,541,000
Issue of common stock for cash in an underwritten public offering, net of expenses (in shares)   61,510          
Warrant exercise (in shares)   3,233          
Stock-based compensation     (2,050,000)   132,000   (1,918,000)
Translation adjustment       2,424,000     2,424,000
Loss for the year           (22,742,000) (22,742,000)
Balance at Dec. 31, 2004   1,000 116,094,000 (1,172,000)   (90,970,000) 23,953,000
Balance (in shares) at Dec. 31, 2004   950,962          
Increase (Decrease) in Stockholders' Equity              
Translation adjustment       (1,786,000)     (1,786,000)
Loss for the year           (18,048,000) (18,048,000)
Balance at Dec. 31, 2005   1,000 116,094,000 (2,958,000)   (109,018,000) 4,119,000
Balance (in shares) at Dec. 31, 2005   950,962          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock (in shares)   92,630          
Issue of shares on conversion of bridging loan and Loan Note Instrument (in shares)   65,187          
Reverse Acquisition 2,000   16,253,000       16,255,000
Reverse Acquisition (in shares) 2,046,813 281,133          
Loan from Cyclacel Group plc waived     10,420,000       10,420,000
Issue of common stock and warrants for cash   1,000 42,361,000       42,362,000
Issue of common stock and warrants for cash (in shares)   918,367          
Stock-based compensation     9,600,000       9,600,000
Change in unrealized loss on investment       5,000     5,000
Translation adjustment       416,000     416,000
Loss for the year           (29,258,000) (29,258,000)
Balance at Dec. 31, 2006 2,000 2,000 194,728,000 (2,537,000)   (138,276,000) 53,919,000
Balance (in shares) at Dec. 31, 2006 2,046,813 2,308,279          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock for cash in an underwritten public offering, net of expenses   1,000 33,356,000       33,357,000
Issue of common stock for cash in an underwritten public offering, net of expenses (in shares)   607,095          
Issue of warrants in connection with registered direct offering     (6,750,000)       (6,750,000)
Issue of common stock upon exercise of stock options     163,000       163,000
Issue of common stock upon exercise of stock options (in shares)   3,644          
Stock-based compensation     1,733,000       1,733,000
Preferred stock dividends declared     (307,000)       (307,000)
Translation adjustment       (93,000)     (93,000)
Loss for the year           (24,053,000) (24,053,000)
Comprehensive loss for the year             (24,146,000)
Balance at Dec. 31, 2007 2,000 3,000 222,923,000 (2,630,000)   (162,329,000) 57,969,000
Balance (in shares) at Dec. 31, 2007 2,046,813 2,919,018          
Increase (Decrease) in Stockholders' Equity              
Stock-based compensation     1,698,000       1,698,000
Preferred stock dividends declared     (1,227,000)       (1,227,000)
Unrealized foreign exchange on intercompany loans       (12,330,000)     (12,330,000)
Translation adjustment       14,918,000     14,918,000
Loss for the year           (40,386,000) (40,386,000)
Balance at Dec. 31, 2008 2,000 3,000 223,394,000 (42,000)   (202,715,000) 20,642,000
Balance (in shares) at Dec. 31, 2008 2,046,813 2,919,018          
Increase (Decrease) in Stockholders' Equity              
Warrant re-pricing     44,000       44,000
Issue of common stock for cash in an underwritten public offering, net of expenses   1,000 2,846,000       2,847,000
Issue of common stock for cash in an underwritten public offering, net of expenses (in shares)   571,429          
Issue of common stock upon draw down of Committed Equity Finance Facility     1,030,000       1,030,000
Issue of common stock upon draw down of Committed Equity Finance Facility (in shares)   179,289          
Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock     7,000       7,000
Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock (in shares)   7,887          
Stock-based compensation     810,000       810,000
Unrealized foreign exchange on intercompany loans       5,651,000     5,651,000
Translation adjustment       (5,589,000)     (5,589,000)
Loss for the year           (19,570,000) (19,570,000)
Balance at Dec. 31, 2009 2,000 4,000 228,131,000 20,000   (222,285,000) 5,872,000
Balance (in shares) at Dec. 31, 2009 2,046,813 3,677,623          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock for cash in an underwritten public offering, net of expenses   1,000 11,896,000       11,897,000
Issue of common stock for cash in an underwritten public offering, net of expenses (in shares)   742,857          
Issue of common stock upon draw down of Committed Equity Finance Facility     4,863,000       4,863,000
Issue of common stock upon draw down of Committed Equity Finance Facility (in shares)   402,704          
Warrant exercise     2,499,000       2,499,000
Warrant exercise (in shares)   374,038          
Issue of common stock on private placement, net of expenses   1,000 13,979,000       13,980,000
Issue of common stock on private placement, net of expenses (in shares)   1,189,028          
Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock     77,000       77,000
Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock (in shares)   29,367          
Preferred stock conversion (1,000)   3,516,000     (3,515,000)  
Preferred stock conversion (in shares) (833,671) 236,514          
Stock-based compensation     1,746,000       1,746,000
Unrealized foreign exchange on intercompany loans       (2,073,000)     (2,073,000)
Translation adjustment       2,084,000     2,084,000
Loss for the year           (16,021,000) (16,021,000)
Balance at Dec. 31, 2010 1,000 7,000 266,706,000 31,000   (241,821,000) 24,924,000
Balance (in shares) at Dec. 31, 2010 1,213,142 6,652,131          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock for cash in an underwritten public offering, net of expenses   1,000 9,271,000       9,272,000
Issue of common stock for cash in an underwritten public offering, net of expenses (in shares)   1,088,235          
Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock     3,000       3,000
Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock (in shares)   5,414          
Issue of common stock upon exercise of stock options             3,000
Issue of common stock upon exercise of stock options (in shares)             948
Stock-based compensation     882,000       882,000
Preferred stock dividends declared     (364,000)       (364,000)
Unrealized foreign exchange on intercompany loans       (622,000)     (622,000)
Translation adjustment       648,000     648,000
Loss for the year           (15,243,000) (15,243,000)
Balance at Dec. 31, 2011 1,000 8,000 276,498,000 57,000   (257,064,000) 19,500,000
Balance (in shares) at Dec. 31, 2011 1,213,142 7,745,780          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock on private placement, net of expenses   1,000 1,821,000       1,822,000
Issue of common stock on private placement, net of expenses (in shares)   669,726          
Issue of common stock on share purchase agreement     1,418,000       1,418,000
Issue of common stock on share purchase agreement (in shares)   233,530          
Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock     94,000       94,000
Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock (in shares)   37,448          
Issue of common stock upon exercise of stock options             100,000
Issue of common stock upon exercise of stock options (in shares)             33,351
Stock-based compensation     380,000       380,000
Unrealized foreign exchange on intercompany loans       4,550,000     4,550,000
Translation adjustment       (4,559,000)     (4,559,000)
Loss for the year           (13,186,000) (13,186,000)
Balance at Dec. 31, 2012 1,000 9,000 280,211,000 48,000 0 (270,250,000) 10,019,000
Balance (in shares) at Dec. 31, 2012 1,213,142 8,686,484          
Increase (Decrease) in Stockholders' Equity              
Issue of common stock for cash in an underwritten public offering, net of expenses   6,000 19,000,000       19,006,000
Issue of common stock for cash in an underwritten public offering, net of expenses (in shares)   6,833,334          
Issue of common stock on share purchase agreement   2,000 9,124,000       9,126,000
Issue of common stock on share purchase agreement (in shares)   2,133,401          
Preferred stock conversion (1,000) 2,000 9,026,000     (9,027,000)  
Preferred stock conversion (in shares) (877,869) 1,684,471          
Issue of shares in lieu of cash bonus     181,000       181,000
Issue of shares in lieu of cash bonus (in shares)   31,642          
Stock-based compensation     357,000       357,000
Preferred stock dividends     (356,000)       (356,000)
Unrealized foreign exchange on intercompany loans       2,751,000     2,751,000
Translation adjustment       (2,908,000)     (2,908,000)
Loss for the year           (10,153,000) (10,153,000)
Balance at Dec. 31, 2013   $ 19,000 $ 317,543,000 $ (109,000)   $ (289,430,000) $ 28,023,000
Balance (in shares) at Dec. 31, 2013 335,273 19,369,332